Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the management of bleeding disorders that involve a deficiency of factor VIII, von Willebrand factor, or both.

• Treatment of hemophilia A patients with severe or moderate factor VIII deficiency.
• Management of von Willebrand disease type 3 and other severe von Willebrand disease forms.
• Control of acute bleeding episodes in individuals with combined factor VIII/von Willebrand factor deficiency.
• Perioperative prophylaxis to prevent surgical or dental bleeding in affected patients.
• Long‑term prophylactic therapy to reduce the frequency of spontaneous bleeds in hemophilia A.

Adverse reactions reported with Haemate P reflect the typical safety profile of plasma‑derived clotting factor concentrates.

Common

• Mild infusion‑related reactions such as headache, nausea, chills, or low‑grade fever.
• Transient elevation of liver enzymes (ALT/AST) that typically resolves without intervention.
• Localized pain, swelling, or erythema at the injection site.
• Mild allergic manifestations including urticaria, pruritus, or flushing.

Serious

• Anaphylactic or severe hypersensitivity reactions requiring emergency medical treatment.
• Development of neutralizing inhibitors against factor VIII, which may reduce therapeutic efficacy.
• Thromboembolic events, including deep‑vein thrombosis or pulmonary embolism, especially in patients with additional risk factors.
• Potential transmission of blood‑borne pathogens despite rigorous donor screening and viral inactivation steps.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure safe use.

• Assess for a history of inhibitors to factor VIII before initiating therapy.
• Verify negative screening for blood‑borne infections (HIV, hepatitis B/C) in the product batch.
• Use caution in patients with a known hypersensitivity to plasma‑derived proteins.
• Monitor for signs of thrombosis, especially in individuals with cardiovascular risk factors.
• Adjust dosing in patients with renal or hepatic impairment as clinical judgment dictates.
• Avoid use in patients with uncontrolled hypertension or active disseminated intravascular coagulation.

Haemate P may interact with other agents that affect coagulation or immune response.

Avoid

• Concurrent use of other activated clotting factor concentrates without medical supervision.
• Administration of high‑dose pro‑coagulant agents (e.g., recombinant factor VIIa) in the same treatment episode.

Use with caution

• Antifibrinolytic drugs such as tranexamic acid, which can increase clot stability.
• Immunosuppressive therapies that may alter inhibitor development risk.
• Concomitant anticoagulants (e.g., warfarin, direct oral anticoagulants) that could counteract hemostatic effect.
• Vaccines or biologics administered shortly before or after infusion, which might affect immune response.